Ultivue,the innovation leader in tissue biomarker identification and quantification assays for translational and pathology research labs, today announced the close of a $22 Million Series C funding led by fresh investor Northpond Ventures and fueled by existing investors including ARCH Venture Partners, and 6 Dimensions Capital,Yonghua Capital, and Applied Ventures.
Source: the-scientist.com